Severe Hemophilia A Without Inhibitor Clinical Trial
Official title:
Comparison of Outcomes Between Low Dose Emicizumab and Extended Half-life Factor VIII With Pharmacokinetic-guided Prophylaxis in Clinically Severe Hemophilia A
- To outcome between low dose Emicizumab and low dose prophylaxis with FVIII concentration - To study pharmacokinetic, side effect of low dose Emicizumab
- To compare outcome between low dose Emicizumab and low dose prophylaxis with FVIII concentration using ABR, AJBR and HJHS, HaemoQoL - To study pharmacokinetic, side effect and effectiveness of low dose Emicizumab ;